DUBLIN--(BUSINESS WIRE)--The "Isocitrate Dehydrogenase (IDH) inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Isocitrate Dehydrogenase (IDH) inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2018 provides comprehensive insights about marketed and pipeline drugs across this mechanism of action. The report provides the detailed analysis of 8+ products along with 5+ companies involved. Agios Pharmaceuticals and Novartis are developing therapeutic drugs in the higher phase and Agios has been granted Orphan and Fast-track Designation both from the FDA.
Products covered by Phase:
- Phase III, Phase II and Phase I
- Pre-clinical and Discovery
Overview of pipeline development activities for Isocitrate Dehydrogenase IDH inhibitors
- Pipeline analysis of 8+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.
- Therapeutic segmentation of products for Isocitrate Dehydrogenase (IDH) inhibitors.
- The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this mechanism of action.
- The report provides competitive pipeline landscape of Isocitrate Dehydrogenase (IDH) inhibitors
- The report provides the marketed drugs information including its sales, development activities and details of patent expiry
- The report provides the insight of current and future market for Isocitrate Dehydrogenase (IDH) inhibitors
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Isocitrate Dehydrogenase (IDH) inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Isocitrate Dehydrogenase (IDH) inhibitors and also provide company profiling
- Pipeline products coverage based on various stages of development ranging from late stage till discovery stage
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
- Celgene Corporation
- Agios Pharmaceuticals
- Daiichi Sankyo Company
- Agios Pharmaceuticals
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/m3clpb/isocitrate?w=4